Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

FDA Approves Abbott's FreeStyle InsuLinx Blood Glucose Monitoring System

RELATED NEWS
Trade ABT now with 

Abbott Laboratories (ABT: Quote) announced that it has received U.S. Food and Drug Administration clearance for the FreeStyle InsuLinx Blood Glucose Monitoring System. The company said that the system included a touch-screen interface, automated logbook. The system also offers Personalization features, including the ability to upload weekly messages, pre-and post-meal markers and a personal photograph to the home screen.

This unique device is also equipped with built-in FreeStyle Auto-Assist software that enables patients to track progress, analyze trends and easily display data for their health care providers.

The FreeStyle InsuLinx System will be available to U.S. consumers within the coming months, the company said.

Click here to receive FREE breaking news email alerts for Abbott Laboratories and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Russia has agreed to resume gas supplies to Ukraine under a $4.6 billion dollar winter package, which will also secure gas for the European Union as the cold season approaches. The European Union has been mediating discussions to help find a sustainable solution to the dispute between Russia and Ukraine over gas pricing, supply and payment dues. After seven rounds of negotiations in recent months The Bank of Japan expanded its massive quantitative and qualitative easing unexpectedly as policymakers assessed it necessary to achieve the 2 percent inflation target even after a sales tax hike in April. In a 5-4 vote, the Policy Board led by Governor Haruhiko Kuroda decided to raise the monetary base at an annual pace of about JPY 80 trillion. LinkedIn Corp., the world's largest online professional network, said Thursday after the markets closed that its third quarter loss widened slightly from last year, as higher costs and expenses more than offset a 45% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.